Showing 1681-1690 of 2314 results for "".
- DORC Announces FDA Approval of TissueBlue for Staining of the ILM During Vitreoretinal Surgeryhttps://modernod.com/news/dorc-announces-fda-approval-of-tissueblue-for-staining-of-the-ilm-during-vitreoretinal-surgery/2477204/Dutch Ophthalmic Research Centre (DORC) announced it has received FDA approval for TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025%. TissueBlue is the first FDA-approved dye for use as an aid in ophthal
- ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-announces-first-patient-dosed-in-phase-1-2-aurora-trial-of-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477159/ProQR Therapeutics announced the first patient dosed in the phase 1/2 Aurora clinical trial of QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP). Initial data from the study are expected in 2021. “From previous clinical trials we have seen that RNA therapies can be a
- CooperVision Earns Global Impact Award for Rebate Donation Program Resulting in $800,000 Raised for Optometry Giving Sighthttps://modernod.com/news/coopervision-earns-global-impact-award-for-rebate-donation-program-resulting-in-800000-raised-for-optometry-giving-sight/2477119/CooperVision offers a contact lens rebate donation program that enables consumers to designate all or part of their rebates to be given to Optometry Giving Sight (OGS). Seven years after the launch of that program, CooperVision has been recognized by 360insights, the company’s rebate and incentiv
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Bausch + Lomb and TerraCycle Announce Donation of New Custom Training Modules to Guide Dog Foundationhttps://modernod.com/news/bausch-lomb-and-terracycle-announce-donation-of-new-custom-training-modules-to-guide-dog-foundation/2477087/Bausch + Lomb in collaboration with TerraCycle, a leader in the collection and repurposing of hard-to-recycle post-consumer waste, announced the donation of custom training modules to the Guide Dog Foundation, a national not-for-profit that trains guide dogs for people who are blind or visually i
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- Phase 3 Study Shows Teprotumumab Significantly Reduced Double Vision for People with Active Thyroid Eye Diseasehttps://modernod.com/news/new-data-from-teprotumumab-phase-3-study-shows-significantly-reduced-double-vision-for-people-with-active-thyroid-eye-disease/2476988/Horizon Therapeutics announced new data from the phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical ac
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary
- DORC Obtains 510k Clearance for Launch of EVA Upgrade Enhancementshttps://modernod.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/DORC has announced 510(k) clearance for a range of enhancements to the EVA surgical system. The enhancements has been developed in close collaboration with surgeons and deliver both OR efficiency and surgical performa
- Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/Ocular Therapeutix announced that it has dosed the first patients in its phase 3 clinical trial of Dextenza for the treatment of symptoms of allergic conjunctivitis. Allergic conjunctivitis refers to inflammation of the conjunctiva of the eye caused by an allergic reaction–generally from airborne